deltatrials
Recruiting PHASE2 INTERVENTIONAL 1-arm NCT07275840

A Study to Evaluate the Efficacy and Safety of IBI302inSubjects With nAMD

An Open-label, Multicenter, Single-arm Phase II Clinical Study Evaluating the Efficacy and Safety of Intravitreal Injection of IBI302 in Participants With Neovascular Age-related Macular Degeneration

Sponsor: Innovent Biologics Technology Limited (Shanghai R&D Center)

Conditions Neovascular Age-related Macular Degeneration
Interventions IBI302 8mg dose
Updated 2 times since 2026 Last updated: Jan 7, 2026 Started: Dec 5, 2025 Primary completion: Aug 30, 2026 Completion: Aug 30, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Neovascular Age-related Macular Degeneration and is currently actively recruiting participants. Innovent Biologics Technology Limited (Shanghai R&D Center) leads this study, which shows 2 recorded versions since 2025 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Jan 2026 – ~Feb 2026 · 31 days · monthly snapshotNot Yet Recruiting~Feb 2026 – present · 5 months · monthly snapshotRecruiting

Change History

2 versions recorded

  1. Feb 2026 — Present [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  2. Jan 2026 — Feb 2026 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Dec 2025

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Innovent Biologics Technology Limited (Shanghai R&D Center)
Data source: Innovent Biologics Technology Limited (Shanghai R&D Center)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations